THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE
.
Main Author: | artilce Editorial |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA PRESS LLC
2017-01-01
|
Series: | Научно-практическая ревматология |
Online Access: | http://rsp.ima-press.net/rsp/article/view/2369 |
Similar Items
-
THE EXPERT BOARD'S ABSTRACT ON QUESTIONS OF THE SURVIVAL OF BIOLOGICAL AGENTS AND THE POSSIBILITY OF SWITCHING TO SECUKINUMAB IN ANKYLOSING SPONDYLITIS IN REAL CLINICAL PRACTICE
by: artilce Editorial
Published: (2017-04-01) -
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016-10-01) -
Role of secukinumab in ankylosing spondylitis with tubercular uveitis
by: Padmamalini Mahendradas, et al.
Published: (2020-01-01) -
Real-world data on secukinumab use for psoriatic arthritis and ankylosing spondylitis
by: Ashley Elliott, et al.
Published: (2019-06-01) -
Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
by: Oh Chan Kwon, et al.
Published: (2021-04-01)